116 related articles for article (PubMed ID: 35347026)
1. CD133(+)HIF-1α(-) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer.
Tachikawa Y; Kawai K; Ozaki K; Nozawa H; Sasaki K; Murono K; Emoto S; Kishikawa J; Yokoyama Y; Abe S; Nagai Y; Anzai H; Sonoda H; Ishihara S
Anticancer Res; 2022 Apr; 42(4):2033-2043. PubMed ID: 35347026
[TBL] [Abstract][Full Text] [Related]
2. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
[TBL] [Abstract][Full Text] [Related]
4. Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer.
Shioya M; Takahashi T; Ishikawa H; Sakurai H; Ebara T; Suzuki Y; Saitoh J; Ohno T; Asao T; Kuwano H; Nakano T
J Radiat Res; 2011; 52(6):821-7. PubMed ID: 22104271
[TBL] [Abstract][Full Text] [Related]
5. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
[TBL] [Abstract][Full Text] [Related]
6. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
[TBL] [Abstract][Full Text] [Related]
8. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.
Lin CH; Chen WT; Liu CH; Tsai HP; Wu CC; Chai CY
Virchows Arch; 2012 May; 460(5):447-53. PubMed ID: 22453233
[TBL] [Abstract][Full Text] [Related]
9. Immunohistological expression of HIF-1α, GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer.
Havelund BM; Sørensen FB; Pløen J; Lindebjerg J; Spindler KL; Jakobsen A
APMIS; 2013 Feb; 121(2):127-38. PubMed ID: 23030583
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis.
Rasheed S; Harris AL; Tekkis PP; Turley H; Silver A; McDonald PJ; Talbot IC; Glynne-Jones R; Northover JM; Guenther T
Br J Cancer; 2009 May; 100(10):1666-73. PubMed ID: 19436307
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer.
Hongo K; Kazama S; Sunami E; Tsuno NH; Takahashi K; Nagawa H; Kitayama J
Med Oncol; 2012 Dec; 29(4):2849-57. PubMed ID: 22246526
[TBL] [Abstract][Full Text] [Related]
13. Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer.
Kawai K; Kitayama J; Tsuno NH; Sunami E; Watanabe T
Int J Colorectal Dis; 2013 Apr; 28(4):527-35. PubMed ID: 23080345
[TBL] [Abstract][Full Text] [Related]
14. CD133 Expression Predicts Relapse in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemotherapy.
Oi H; Okuyama T; Miyazaki S; Ono Y; Oya M
In Vivo; 2021; 35(1):437-445. PubMed ID: 33402494
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Apr; 21(2):350-358. PubMed ID: 26370256
[TBL] [Abstract][Full Text] [Related]
17. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer.
Shim BY; Jung JH; Lee KM; Kim HJ; Hong SH; Kim SH; Sun DS; Cho HM
Int J Colorectal Dis; 2013 Mar; 28(3):375-83. PubMed ID: 22847606
[TBL] [Abstract][Full Text] [Related]
18. Survivin expression can predict the effect of chemoradiotherapy for advanced lower rectal cancer.
Takasu C; Shimada M; Kurita N; Iwata T; Sato H; Nishioka M; Morimoto S; Yoshikawa K; Miyatani T; Kashihara H; Utsunomiya T; Uehara H
Int J Clin Oncol; 2013 Oct; 18(5):869-76. PubMed ID: 22936565
[TBL] [Abstract][Full Text] [Related]
19. Preoperative radiotherapy downregulates the nuclear expression of hypoxia-inducible factor-1alpha in rectal cancer.
Korkeila E; Jaakkola PM; Syrjänen K; Sundström J; Pyrhönen S
Scand J Gastroenterol; 2010 Mar; 45(3):340-8. PubMed ID: 20001759
[TBL] [Abstract][Full Text] [Related]
20. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
